Thyrocare Technologies Limited, one of India’s leading diagnostic service providers, has announced strong financial results for the quarter ended June 30, 2025 (Q1FY26). The company reported a 23% year-on-year (YoY) jump in consolidated revenue, reaching ₹193.03 crore, compared to ₹156.91 crore in the same quarter last year.
This growth was primarily led by a robust 25% increase in its pathology business and a 6% uptick in radiology. Within pathology, the franchise segment grew by 20% YoY, while the partnership model revenue surged by 36% YoY. The company processed 46.9 million tests during the quarter, up 15% from Q1FY25.
Gross margin remained stable at 71%, and the normalized EBITDA (before ESOP costs) rose 42% YoY to ₹63.35 crore. EBITDA stood at ₹57.46 crore, marking a 37% increase from the previous year. Profit after tax, including exceptional items, came in at ₹38.06 crore—registering a sharp 62% rise YoY.
The company’s profitability also improved on a margin basis, with normalized EBITDA margin rising to 33%, reported EBITDA margin at 30%, and PAT margin climbing to 20%.
In terms of expansion, Thyrocare added new laboratories in Bhagalpur, Kashmir, and Roorkee, strengthening its presence across Tier 2 and Tier 3 markets.
With strong growth across core business segments, improving margins, and strategic expansion, Thyrocare continues to solidify its position as a key player in India’s diagnostic healthcare sector.
